Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 26, Number 3—March 2020

Research

Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1

Joanne M. LangleyComments to Author , Soren Gantt, Caroline Quach, Julie A. Bettinger, Scott A. Halperin, Jill Mutch, Shelly A. McNeil, Brian J. Ward, Donna MacKinnon-Cameron, Lingyun Ye, Kim Marty, David Scheifele, Erin Brown, Joenel Alcantara, and The Canadian Immunization Research Network
Author affiliations: Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and Nova Scotia Health Authority, Halifax, Nova Scotia, Canada (J.M. Langley, S.A. Halperin, J. Mutch, S.A. McNeil, D. MacKinnon-Cameron, L. Ye); Vaccine Evaluation Center, University of British Columbia, Vancouver, British Columbia, Canada (S. Gantt, J.A. Bettinger, K. Marty, D. Scheifele); University of Montreal, Montreal, Quebec, Canada (C. Quach); Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada (C. Quach, B.J. Ward); University of Calgary, Calgary, Alberta, Canada (E. Brown, J. Alcantara)

Main Article

Table 2

Percentage of participants with hSBA titers >1:4 by strain in a trial of MenB-4C vaccine from day 0 to day 180, Canada*

Meningococcal strain
 Participants with hSBA, % (95% CI)
Day 0
 Day 21
 Day 42
 Day 81
 Day 180
5/99
Accelerated 67.2 (53.7–79.0) 100 (93.8–100) 100 (93.7–100) 100 (93.7–100) 100 (93.7–100)
Longer interval
 89.7 (78.8–96.1)
 98.3 (90.8–100)
 98.3 (90.8–100)
 100 (93.8–100)
 100 (93.7–100)
H44/76
Accelerated 20.7 (11.2–33.4) 98.3 (90.8–100) 98.2 (90.6–100) 98.2 (90.6–100) 96.5 (87.9–99.6)
Longer interval
 43.1 (30.2–56.8)
 98.3 (90.8–100)
 96.6 (88.1–99.6)
 100 (93.8–100)
 100 (93.7–100)
NZ98/254
Accelerated 51.7 (38.2–65.0) 98.3 (90.8–100) 100 (93.7–100) 100 (93.7–100) 98.2 (90.6–100)
Longer interval 65.5 (51.9–77.5) 100 (93.8–100) 100 (93.8–100) 100 (93.8–100) 98.2 (90.6–100)

*The accelerated schedule was MenB-4C vaccine at 0 and 21 days. The longer interval schedule was MenB-4C vaccine at 0 and 60 days. 5/99, Neisserial adhesin A surface proteins; H44/76, factor H binding protein; hSBA, human serum bactericidal antibody; MenB, Neisseria meningitidis serotype B; MenB-4C, 4-component protein-based menB; NZ98/254, New Zealand outer membrane vesicle.

Main Article

1Preliminary results from this study were presented at IDWeek, October 26–30, 2016, New Orleans, LA, USA; and at the Meningitis Research Foundation Conference, November 14–15, 2017, London, England, UK.

Page created: February 19, 2020
Page updated: February 19, 2020
Page reviewed: February 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external